OUR GLOBAL WEBSITE +90 212 281 81 60 [email protected]

ABOUT US OAKLINS

OUR SERVICES

Overview

Inhera offers M&A and corporate finance solutions that combine local expertise with global reach — creating value through every transaction.

Sell Side Advisory

Selling a company is a critical decision of the upmost importance for any business owner and a complex process that must be handled delicately.

Buy Side Advisory

We advise financial and strategic buyers to enter or expand in Turkey, grow geographically, consolidate fragmented industries, and expand their product and service offering.

Private Equity Transactions

We advise companies to raise equity or mezzanine financing and / or sell minority or majority shares to private equity funds, mezzanine lenders, and hedge funds.

Initial Public Offering (IPO) Advisory

We prepare companies for IPO by optimizing readiness, timing, and market positioning to support optimal valuation at public offerings.

Debt Advisory

Inhera Capital provides a full spectrum of debt services including acquisition, growth financing and project finance to perfectly match the needs of our clients. Our services can be useful in complicated, sizable financing deals that require value-added analysis, projections and processing.

Restructuring and Distressed M&A

We can bring exceptional benefit when our clients are in financial distress by preserving and augmenting remaining value through…

OUR EXPERIENCE

OUR INDUSTRIES OUR TEAM CAREERS CONTACT US

NOVARTIS SANDOZ has merged with Hexal

Novartis has acquired Hexal AG, a Germany-based generic pharmaceuticals company, and integrated it into Sandoz, Novartis’ generics division. Hexal is one of Germany’s leading generic pharmaceutical companies, with a broad product portfolio, strong development capabilities and an established position in the German generics market. The company has built significant expertise in the development, registration and commercialization of generic medicines. Sandoz is Novartis’ global generics division, with a broad portfolio of off-patent medicines and a strong international commercial footprint. Through the integration of Hexal, Sandoz significantly strengthened its position in Germany and other key markets, expanded its product portfolio and reinforced its platform in the global generics industry. INHERA acted as financial and strategic advisor to Sandoz in this transaction.